Sionna Therapeutics (NASDAQ:SION) Rating Lowered to “Market Perform” at Raymond James Financial

Sionna Therapeutics (NASDAQ:SION) was downgraded by investment analysts at Raymond James Financial from a “strong-buy” rating to a “market perform” rating in a research note issued to investors on Monday.

Several other research firms also recently commented on SION. JonesTrading boosted their price objective on Sionna Therapeutics from $52.00 to $63.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Guggenheim raised their price objective on shares of Sionna Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Friday. Stifel Nicolaus reissued a “hold” rating and set a $7.00 target price on shares of Sionna Therapeutics in a research report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Wednesday. Finally, Citizens Jmp reissued a “market outperform” rating and issued a $63.00 price objective on shares of Sionna Therapeutics in a research note on Tuesday, May 26th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Sionna Therapeutics has an average rating of “Hold” and an average target price of $42.22.

Sionna Therapeutics Stock Down 92.1%

NASDAQ:SION traded down $46.98 during trading hours on Monday, reaching $4.05. The company had a trading volume of 23,315,454 shares, compared to its average volume of 548,288. Sionna Therapeutics has a twelve month low of $4.01 and a twelve month high of $54.97. The firm has a market cap of $183.33 million, a price-to-earnings ratio of -1.88 and a beta of 1.32. The business’s 50-day simple moving average is $42.35 and its two-hundred day simple moving average is $40.42.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.02). As a group, equities analysts predict that Sionna Therapeutics will post -2.63 earnings per share for the current year.

Insider Buying and Selling at Sionna Therapeutics

In other Sionna Therapeutics news, Director Peter A. Thompson sold 115,844 shares of the business’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $45.50, for a total value of $5,270,902.00. Following the transaction, the director owned 2,555,877 shares of the company’s stock, valued at approximately $116,292,403.50. The trade was a 4.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 115,844 shares of Sionna Therapeutics stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $45.50, for a total value of $5,270,902.00. Following the sale, the director owned 2,555,877 shares in the company, valued at $116,292,403.50. The trade was a 4.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 403,726 shares of company stock worth $18,259,354. Insiders own 5.10% of the company’s stock.

Institutional Trading of Sionna Therapeutics

Large investors have recently bought and sold shares of the company. Russell Investments Group Ltd. purchased a new position in shares of Sionna Therapeutics during the 3rd quarter valued at $30,000. BNP Paribas Financial Markets bought a new stake in Sionna Therapeutics in the 2nd quarter valued at about $31,000. State of Wyoming purchased a new stake in Sionna Therapeutics during the second quarter valued at about $35,000. GF Fund Management CO. LTD. bought a new position in Sionna Therapeutics during the fourth quarter worth about $36,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Sionna Therapeutics during the second quarter worth about $44,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.